| Description |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have garnered significant attention and controversy as potential miracle drugs for obesity and type 2 diabetes mellitus (T2DM). Recent studies suggest GLP-1 RAs have expanded indications beyond their original purpose. Current off-label research is exploring the possible treatment for a range of conditions, including Parkinson's disease, Alzheimer's disease, chronic kidney disease, infertility, cardiovascular diseases, mental health conditions, substance addictions, and musculoskeletal conditions. This expansion of research suggests GLP-1 RAs could offer valuable treatment options in non-diabetic populations. This research seeks to identify and evaluate the efficacy of GLP-1 RAs in conditions beyond T2DM and obesity, through a state-of-science review. The goal is to denote the effectiveness and safety standards for GLP-1 RAs in treating various diseases beyond the diabetic population. This research highlights therapeutic potentials, acknowledges the challenges of GLP-1 RAs for the patient and provider, and seeks to discern evidence-based protocols for future treatments. This is a coordinated, systematic collection of emerging uses for GLP-1 RAs in non-diabetic circumstances. Continued research clarification is needed for long-term safety, optimal dosing standards, and appropriate treatment selection beyond established glycemic control benchmarking. |
